AbClon Inc. (KOSDAQ:174900)

South Korea flag South Korea · Delayed Price · Currency is KRW
61,800
-900 (-1.44%)
Feb 27, 2026, 3:30 PM KST
Market Cap1.23T +441.9%
Revenue (ttm)3.80B +73.3%
Net Income-16.23B
EPS-895.81
Shares Out19.93M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume224,083
Average Volume301,407
Open62,700
Previous Close62,700
Day's Range59,900 - 64,000
52-Week Range6,810 - 70,000
Beta1.22
RSI54.52
Earnings Daten/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea. [Read more]

Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 174900
Full Company Profile

Financial Performance

In 2024, AbClon's revenue was 2.34 billion, a decrease of -18.67% compared to the previous year's 2.88 billion. Losses were -16.42 billion, 27.2% more than in 2023.

Financial Statements